4,901 trials
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions — 112,236.7; 154,676.6 ng*hr/mL
Healthy
Primary: Area Under the Steady-state Plasma Concentration-time Curve (AUClast) of SSP-004184 After One Dose — 261901.9; 164340 ng*h/mL
Human Volunteers
Primary: Comparison Between INVOS Monitoring and Electromyography — 73; 46 % of StcO2
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 21960.6; 25414.8; 931.8; 1062.6 ng/mL
Epilepsy
Primary: QTcI - QT Interval Individually Corrected for Heart Rate - Day 5 — -8.05; -6.15; -2.77; -4.39 msec
Hepatic Impairment
Primary: Pharmacokinetic Parameters of BAF312 and Selected Metabolites: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) — 68.3; 53.9; 73.7…
Kidney Failure, Chronic Therapy; Hemodialysis
Primary: Pharmacokinetics of Iron From Soluble Ferric Pyrophosphate: Cohorts 1, 2, 3, 6 (Mean Total Serum Iron, Baseline Corrected) — 18.87125; 14.625; 20.13333; 14.806…
Liver Cirrhosis
Primary: Number of Participants With Severe Adverse Events — 0; 0; 0 participants
Epilepsy
Primary: Number of Adverse Events Reported — 6; 6; 1; 5 Number of adverse events reported
Partial Epilepsy
Primary: Cmax - Maximum Plasma Concentration in Plasma and Cerebral Spinal Fluid — 23932; 16162; 886; 4039 ng/mL
Epilepsy
Primary: Cmax - the Maximum Plasma Concentration — 16350.6; 23806.5; 976.9; 954.3 ng/mL
Neuropathic Pain
Primary: Cmax - Maximum Observed Plasma Concentration — 1091; 1224 ng/mL
Partial Epilepsy
Primary: Cmax - Maximum Observed Plasma Concentration — 82.4; 75.0; 4170; 4340 pg/mL
Epilepsy
Primary: Maximum Observed Plasma Concentration (Cmax) — 11302; 12799 ng/mL
Plaque Psoriasis
Primary: Number of Participants With an Adverse Event of Erythema in Part I of the Study — 0; 0 Participants